About CoRegen
CoRegen is a private company based in Houston, Texas, incorporated in 2022 in Delaware. It has reported $134,260,002 raised in six offerings on Form D since March 2024.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 28, 2025 | Feb 26, 2026 | $13,500,000fully sold | 1 | $13.5M | EquityRule 506(b) | Form D ↗ |
| Apr 21, 2025 | May 22, 2025 | $62,640,000fully sold | 8 | $7.8M | EquityRule 506(b) | Form D ↗ |
| Feb 3, 2025 | Feb 28, 2025 | $10,000,002fully sold | 1 | $10.0M | EquityRule 506(b) | Form D ↗ |
| Jan 19, 2025 | Feb 28, 2025 | $20,750,000fully sold | 7 | $2.9M | EquityRule 506(b) | Form D ↗ |
| Aug 9, 2022 | Mar 8, 2024 | $12,870,000fully sold | 31 | $415K | Convertible Note convertible into Series A-2 Preferred StockRule 506(b) | Form D ↗ |
| Feb 8, 2024 | Feb 22, 2024 | $14,500,000target not set | 1 | $14.5M | EquityRule 506(b) | Form D ↗ |
| Total, six offerings | $134,260,002 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on CoRegen's Form D filed Feb 26, 2026.
Earlier filings also listed Lee Fleisher, M.D. (director, last listed May 2025), John Thomas, Jr. (chief financial officer and secretary, last listed May 2025), David Lonard, PhD (chief science officer, last listed May 2025), Clifford Dasco, M.D. (chief medical officer and director, last listed May 2025), Shawn Tomasello (chief executive officer and director, last listed Feb 2025), David Cornell, II (director, last listed Mar 2024) and Bert O'Malley, M.D. (director, last listed Feb 2024).